739 related articles for article (PubMed ID: 17573879)
1. Transformed mycosis fungoides: clinicopathological features and outcome.
Barberio E; Thomas L; Skowron F; Balme B; Dalle S
Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
[TBL] [Abstract][Full Text] [Related]
2. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
4. Mycosis fungoides--analysis of the duration of disease stages in patients who progress and the time point of high-grade transformation.
Kamarashev J; Theler B; Dummer R; Burg G
Int J Dermatol; 2007 Sep; 46(9):930-5. PubMed ID: 17822495
[TBL] [Abstract][Full Text] [Related]
5. Mycosis fungoides--a review of the management of 28 patients and of the recent literature.
Lenane P; Powell FC; O'Keane C; Dervan P; O'Sullivan D; Bourke E; O'Loughlin S
Int J Dermatol; 2007 Jan; 46(1):19-26. PubMed ID: 17214715
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
7. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study.
Wain EM; Orchard GE; Whittaker SJ; Spittle M Sc MF; Russell-Jones R
Cancer; 2003 Nov; 98(10):2282-90. PubMed ID: 14601100
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and course of CD8+ cytotoxic variant of mycosis fungoides: a case series of seven patients.
Nikolaou VA; Papadavid E; Katsambas A; Stratigos AJ; Marinos L; Anagnostou D; Antoniou C
Br J Dermatol; 2009 Oct; 161(4):826-30. PubMed ID: 19558552
[TBL] [Abstract][Full Text] [Related]
9. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
Gerami P; Rosen S; Kuzel T; Boone SL; Guitart J
Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
Suzuki SY; Ito K; Ito M; Kawai K
J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
[TBL] [Abstract][Full Text] [Related]
11. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
12. CD4/CD8 double-negative epidermotropic cutaneous T-cell lymphoma: an immunohistochemical variant of mycosis fungoides.
Hodak E; David M; Maron L; Aviram A; Kaganovsky E; Feinmesser M
J Am Acad Dermatol; 2006 Aug; 55(2):276-84. PubMed ID: 16844512
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
15. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
Meissner K; Löning T; Rehpenning W
Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
[TBL] [Abstract][Full Text] [Related]
16. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides.
Lu D; Duvic M; Medeiros LJ; Luthra R; Dorfman DM; Jones D
Am J Clin Pathol; 2001 Mar; 115(3):413-21. PubMed ID: 11242798
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological spectrum of mycosis fungoides type cutaneous T-cell lymphoma.
Shaikh ZI; Rahman SB
J Coll Physicians Surg Pak; 2006 Mar; 16(3):171-4. PubMed ID: 16542594
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma.
Beljaards RC; Meijer CJ; Van der Putte SC; Hollema H; Geerts ML; Bezemer PD; Willemze R
J Pathol; 1994 Jan; 172(1):53-60. PubMed ID: 7931828
[TBL] [Abstract][Full Text] [Related]
19. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
20. Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases.
Muniesa C; Estrach T; Pujol RM; Gallardo F; Garcia-Muret P; Climent J; Servitje O
J Am Acad Dermatol; 2010 Mar; 62(3):418-26. PubMed ID: 20079954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
